Oral Session 3-7C Hodgkin Lymphoma

[OS3-7C-6] Final results from a Japanese phase 2 study of nivolumab in relapsed/refractory Hodgkin lymphoma

Yasuhito Terui¹, Dai Maruyama², Kazuhito Yamamoto³, Noriko Fukuhara⁴, Ilseung Choi⁵, Junya Kuroda⁶, Kiyoshi Ando⁷, Akira Hattori⁸, Kensei Tobinai² (1.Cancer Inst. Hosp. JFCR, Tokyo, Japan, 2.Natl. Cancer Ctr. Hosp., Tokyo, Japan, 3.Aichi Cancer Ctr., Nagoya, Japan, 4.Tohoku Univ. Grad. Sch. Med., Sendai, Japan, 5.NHO Kyushu Cancer Ctr., Fukuoka, Japan, 6.Kyoto Pref. Univ. Med., Kyoto, Japan, 7.Tokai Univ., Isehara, Japan, 8.Ono Pharmaceutical Co., Ltd, Osaka, Japan)